Source briefingOctober 12, 2026Health & Science
Comparative effectiveness of amlodipine versus nifedipine prescribed at discharge in patients with ischemic stroke or transient ischemic attack: A nationwide 5-year follow-up registry study

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.
What the source reports
by Xinya Li, Xue Xia, Meng Gao, Qin Xu, Yijun Zhang, Jing Jing, Yi Zhai, Xia Meng, Anxin Wang Background Amlodipine and nifedipine are the most commonly prescribed calcium channel blockers (CCB) for patients suffering from ischemic stroke or transient ischemic attack (TIA). Nevertheless, there is a scarcity of direct comparative evidence on their effectiveness.
This study aimed to compare the effectiveness of amlodipine and nifedipine in patients with ischemic stroke or TIA. Methods and findings This observational study was based on…
Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.
Source & verification
Primary source: PLOS Medicine · October 12, 2026
FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.
Continue reading

EMA/PE/0000181364
What is established The European Medicines Agency (EMA) has granted a decision regarding a paediatric investigation plan (PIP) for vosoritide as of 8 August…

EMA/PE/0000228795
Evidence Dossier: EMA Paediatric Investigation Plan for Ambrisentan/Tadalafil What is established The European Medicines Agency (EMA) has officially adopted a paediatric investigation plan (PIP)…

EMA/PE/0000261344
Evidence Dossier: EMA Decision on Colchicine Paediatric Investigation Plan (PIP) What is established On 8 August 2025, the European Medicines Agency (EMA) granted a…